O

Omada Health, Inc. (OMDA)

NMS – Real vaqt narxi. Valyuta: USD

14.91

+0.22 (1.50%)

Yopilishda: May 12, 2026, 4:00 PM EDT

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Barcha huquqlar himoyalangan.

Foydalanish shartlari

O

Omada Health, Inc. (OMDA)

NMS – Real vaqt narxi. Valyuta: USD

14.91

+0.22 (1.50%)

Yopilishda: May 12, 2026, 4:00 PM EDT

08.05.2026

Omada Health Q1 Earnings Call Highlights

Omada Health NASDAQ: OMDA reported what executives described as a “milestone quarter” for the first quarter of 2026, highlighting 42% year-over-year revenue growth, expanding margins, and positive adjusted EBITDA alongside a raised full-year outlook.

08.05.2026

Omada Health, Inc. (OMDA) Q1 2026 Earnings Call Transcript

07.05.2026

Compared to Estimates, Omada Health, Inc. (OMDA) Q1 Earnings: A Look at Key Metrics

Although the revenue and EPS for Omada Health, Inc. (OMDA) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

07.05.2026

Omada Health Joins Lilly Employer Connect, Expanding Its Access Pathways for GLP-1 Care as Patients Seek More Lifestyle Support

SAN FRANCISCO, May 07, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA) announced it will serve as an independent program administrator in Eli Lilly and Company's Employer Connect program. Omada will offer its GLP‑1 Care Track, including clinical evaluation, prescribing, and ongoing medication management, to employers.

07.05.2026

Omada Health Reports First Quarter 2026 Results

Revenue up 42% Year over Year ; Total Members Surpass One Million; Expanded Channels Now Include All Three of the Nation's Leading PBMs SAN FRANCISCO, May 07, 2026 (GLOBE NEWSWIRE) -- Omada Health, Inc. (Nasdaq: OMDA), the virtual between-visit healthcare provider, today reported financial results for the first quarter ended March 31, 2026. Recent Highlights Total Members: 1.02 million Total Members at the end of Q1, up 51% year over year, reinforcing Omada's role as an integrated, multi-condition cardiometabolic platform operating at scale.

17.04.2026

Omada Health Helps Members on GLP‑1s Lose More Fat, Preserve Muscle Mass, and Improve Mental Health, New Study Finds

SAN FRANCISCO, April 17, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual-first provider of between-visit care, announced new study results demonstrating that Omada members in its GLP-1 Care Track lost, on average, 1.8 times more total weight and reduced their body fat percentage twice as much as the comparison group.1 The Omada members also saw an increase in muscle mass percentage and improvements in other well-being measures.1 These findings suggest that Omada's program may optimize the weight loss results of GLP-1s,1 mitigating a key risk of muscle loss associated with GLP-1s.2 Research has shown that during gradual weight loss from lifestyle interventions and older weight loss medications, roughly one-fourth of total weight loss is expected to come from lean mass.3 Popular GLP‑1 medications, such as semaglutide and tirzepatide, typically produce more rapid and substantial weight loss, which is often associated with a higher proportion of lean mass loss.2 One study found that on average, lean mass accounted for around 40% of the weight people lost.4 Omada's 12-week study followed 245 adults with obesity (BMI ≥30), including 151 Omada members and 94 control participants, all of whom had recently started a GLP-1 for weight management.1 It compared a group that was given access to Omada's GLP-1 Care Track–designed as a wraparound program to promote strength training and physical activity with one-on-one support to protect muscle mass and improve overall body composition–to a group that did not receive access to Omada. Both groups used an at-home scale to track weight and body composition and completed surveys to assess emotional health, well-being, self-efficacy, and physical function.

16.04.2026

Omada Health to Announce First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026

SAN FRANCISCO, April 16, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that it will release its first quarter 2026 results on Thursday, May 7, 2026, after market close, and host a conference call to review the results at 4:30 pm ET the same day. Conference Call Details A live audio webcast of the call will be available online at https://investors.omadahealth.com.

Videolar

No Data

There is no data to display

Press-relizlar

07.05.2026

Omada Health Joins Lilly Employer Connect, Expanding Its Access Pathways for GLP-1 Care as Patients Seek More Lifestyle Support

SAN FRANCISCO, May 07, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA) announced it will serve as an independent program administrator in Eli Lilly and Company's Employer Connect program. Omada will offer its GLP‑1 Care Track, including clinical evaluation, prescribing, and ongoing medication management, to employers.

07.05.2026

Omada Health Reports First Quarter 2026 Results

Revenue up 42% Year over Year ; Total Members Surpass One Million; Expanded Channels Now Include All Three of the Nation's Leading PBMs SAN FRANCISCO, May 07, 2026 (GLOBE NEWSWIRE) -- Omada Health, Inc. (Nasdaq: OMDA), the virtual between-visit healthcare provider, today reported financial results for the first quarter ended March 31, 2026. Recent Highlights Total Members: 1.02 million Total Members at the end of Q1, up 51% year over year, reinforcing Omada's role as an integrated, multi-condition cardiometabolic platform operating at scale.

17.04.2026

Omada Health Helps Members on GLP‑1s Lose More Fat, Preserve Muscle Mass, and Improve Mental Health, New Study Finds

SAN FRANCISCO, April 17, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual-first provider of between-visit care, announced new study results demonstrating that Omada members in its GLP-1 Care Track lost, on average, 1.8 times more total weight and reduced their body fat percentage twice as much as the comparison group.1 The Omada members also saw an increase in muscle mass percentage and improvements in other well-being measures.1 These findings suggest that Omada's program may optimize the weight loss results of GLP-1s,1 mitigating a key risk of muscle loss associated with GLP-1s.2 Research has shown that during gradual weight loss from lifestyle interventions and older weight loss medications, roughly one-fourth of total weight loss is expected to come from lean mass.3 Popular GLP‑1 medications, such as semaglutide and tirzepatide, typically produce more rapid and substantial weight loss, which is often associated with a higher proportion of lean mass loss.2 One study found that on average, lean mass accounted for around 40% of the weight people lost.4 Omada's 12-week study followed 245 adults with obesity (BMI ≥30), including 151 Omada members and 94 control participants, all of whom had recently started a GLP-1 for weight management.1 It compared a group that was given access to Omada's GLP-1 Care Track–designed as a wraparound program to promote strength training and physical activity with one-on-one support to protect muscle mass and improve overall body composition–to a group that did not receive access to Omada. Both groups used an at-home scale to track weight and body composition and completed surveys to assess emotional health, well-being, self-efficacy, and physical function.

05.03.2026

Omada Health Announces GLP-1 Flex Care, Giving Employers a New, Flexible Path to Support Obesity Care

SAN FRANCISCO, March 05, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual-first provider of between-visit care, today announced GLP-1 Flex Care, a new offering that will support employers looking to increase access to GLP-1 medications for obesity, including clinical evaluation, prescribing, and ongoing medical guidance and oversight. Members purchase their medications independently through cash-pay channels, helping employers limit their direct exposure to medication costs.

Search stocks

Omada Health, Inc. (OMDA)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Omada Health, Inc. (OMDA)

Omada Health Q1 Earnings Call Highlights

Omada Health, Inc. (OMDA) Q1 2026 Earnings Call Transcript

Compared to Estimates, Omada Health, Inc. (OMDA) Q1 Earnings: A Look at Key Metrics

Omada Health Joins Lilly Employer Connect, Expanding Its Access Pathways for GLP-1 Care as Patients Seek More Lifestyle Support

Omada Health Reports First Quarter 2026 Results

Omada Health Helps Members on GLP‑1s Lose More Fat, Preserve Muscle Mass, and Improve Mental Health, New Study Finds

Omada Health to Announce First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026

Videolar

No Data

Press-relizlar

Omada Health Joins Lilly Employer Connect, Expanding Its Access Pathways for GLP-1 Care as Patients Seek More Lifestyle Support

Omada Health Reports First Quarter 2026 Results

Omada Health Helps Members on GLP‑1s Lose More Fat, Preserve Muscle Mass, and Improve Mental Health, New Study Finds

Omada Health Announces GLP-1 Flex Care, Giving Employers a New, Flexible Path to Support Obesity Care